Wall Street analysts forecast that Pharmerica Corporation (NYSE:PMC) will post $614.00 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Pharmerica Corporation’s earnings, with estimates ranging from $608.00 million to $620.00 million. Pharmerica Corporation reported sales of $534.40 million during the same quarter last year, which would suggest a positive year over year growth rate of 14.9%. The firm is expected to issue its next earnings report on Friday, February 23rd.

On average, analysts expect that Pharmerica Corporation will report full year sales of $614.00 million for the current year, with estimates ranging from $2.36 billion to $2.38 billion. For the next fiscal year, analysts forecast that the business will report sales of $2.61 billion per share, with estimates ranging from $2.59 billion to $2.64 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Pharmerica Corporation.

Pharmerica Corporation (NYSE:PMC) last posted its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.03). The business had revenue of $595.10 million for the quarter, compared to analyst estimates of $596.80 million. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 0.83%.

Several equities research analysts have issued reports on PMC shares. Zacks Investment Research cut Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub cut Pharmerica Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. KeyCorp cut Pharmerica Corporation to an “overweight” rating in a research note on Wednesday, August 2nd. Barrington Research cut Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research note on Thursday, August 3rd. Finally, UBS AG reissued a “neutral” rating and set a $29.25 target price (up previously from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Pharmerica Corporation has a consensus rating of “Hold” and an average target price of $30.50.

Pharmerica Corporation (NYSE PMC) traded down $0.05 during mid-day trading on Wednesday, reaching $29.10. The company’s stock had a trading volume of 198,700 shares, compared to its average volume of 282,120. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.79 and a current ratio of 2.58. The firm has a market capitalization of $907.15, a PE ratio of 15.10, a price-to-earnings-growth ratio of 1.27 and a beta of 0.82. Pharmerica Corporation has a one year low of $22.00 and a one year high of $29.50.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/15/zacks-brokerages-expect-pharmerica-corporation-pmc-will-post-quarterly-sales-of-614-00-million.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in shares of Pharmerica Corporation by 0.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,228 shares of the company’s stock worth $610,000 after buying an additional 71 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Pharmerica Corporation by 0.9% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,614 shares of the company’s stock worth $305,000 after buying an additional 100 shares during the period. Capstone Asset Management Co. boosted its position in shares of Pharmerica Corporation by 0.9% during the second quarter. Capstone Asset Management Co. now owns 16,041 shares of the company’s stock worth $421,000 after buying an additional 150 shares during the period. Louisiana State Employees Retirement System boosted its position in shares of Pharmerica Corporation by 1.6% during the second quarter. Louisiana State Employees Retirement System now owns 12,700 shares of the company’s stock worth $333,000 after buying an additional 200 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of Pharmerica Corporation by 1.2% during the second quarter. Arizona State Retirement System now owns 16,216 shares of the company’s stock worth $426,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 86.49% of the company’s stock.

About Pharmerica Corporation

Get a free copy of the Zacks research report on Pharmerica Corporation (PMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pharmerica Corporation (NYSE:PMC)

Receive News & Stock Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related stocks with our FREE daily email newsletter.